|
1
|
Sibille A, Paulus A, Martin M, Bourhaba M,
Barthélemy N, Radermecker M, Corhay JL, Louis R and Duysinx B:
Management of non-small cell lung cancer. Rev Med Liege.
70:432–441. 2015.(In French). PubMed/NCBI
|
|
2
|
Venkatesulu BP, Mallick S, Singh A and
Julka PK: Non small cell carcinoma of lung with metachronous breast
metastasis and cardiac tamponade: Unusual presentation of a common
cancer. J Egypt Natl Canc Inst. 27:165–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun Z, Wang Z, Liu X and Wang D: New
development of inhibitors targeting the PI3K/AKT/mTOR pathway in
personalized treatment of non-small-cell lung cancer. Anticancer
Drugs. 26:1–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu CF, Fu JY, Yeh CJ, Liu YH, Hsieh MJ, Wu
YC, Wu CY, Tsai YH and Chou WC: Recurrence risk factors analysis
for stage I non-small cell lung cancer. Medicine (Baltimore).
94:e13372015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng B, Zhang K, Wang R and Chen L:
Non-small-cell lung cancer and miRNAs: Novel biomarkers and
promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghasemkhani N, Shadvar S, Masoudi Y,
Talaei AJ, Yahaghi E, Goudarzi PK and Shakiba E: Down-regulated
MicroRNA 148b expression as predictive biomarker and its prognostic
significance associated with clinicopathological features in
non-small-cell lung cancer patients. Diagn Pathol. 10:1642015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bai T, Dong DS and Pei L: Synergistic
antitumor activity of resveratrol and miR-200c in human lung
cancer. Oncol Rep. 31:2293–2297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu
J, Xue J, Liu T, Liang Y and Wu G: MiR-200c increases the
radiosensitivity of non-small-cell lung cancer cell line A549 by
targeting VEGF-VEGFR2 pathway. PLoS One. 8:e783442013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Li X, Ren S, Chen X, Zhang Y, Zhou
F, Zhao M, Zhao C, Chen X, Cheng N, et al: miR-200c overexpression
is associated with better efficacy of EGFR-TKIs in non-small cell
lung cancer patients with EGFR wild-type. Oncotarget. 5:7902–7916.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MK, Jung SB, Kim JS, Roh MS, Lee JH,
Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is
associated with prognosis in patients with non-small cell lung
cancer. Virchows Arch. 465:463–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Li D, Zhuang Y, Shi Q, Wei W and Ju
X: Overexpression of miR-708 and its targets in the childhood
common precursor B-cell ALL. Pediatr Blood Cancer. 60:2060–2067.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hansen O, Schytte T, Nielsen M and Brink
C: Age dependent prognosis in concurrent chemo-radiation of locally
advanced NSCLC. Acta Oncol. 54:333–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strøm HH, Bremnes RM, Sundstrøm SH,
Helbekkmo N and Aasebø U: Poor prognosis patients with inoperable
locally advanced NSCLC and large tumors benefit from palliative
chemoradiotherapy: A subset analysis from a randomized clinical
phase III trial. J Thorac Oncol. 9:825–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu CM, Peng CY, Liao YW, Lu MY, Tsai ML,
Yeh JC, Yu CH and Yu CC: Sulforaphane targets cancer stemness and
tumor initiating properties in oral squamous cell carcinomas via
miR-200c induction. J Formos Med Assoc. 116:41–48. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie Y, Wehrkamp CJ, Li J, Wang Y, Wang Y,
Mott JL and Oupický D: Delivery of miR-200c Mimic with Poly (amido
amine) CXCR4 antagonists for combined inhibition of
cholangiocarcinoma cell invasiveness. Mol Pharm. 13:1073–1080.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Liu J, Qu D, Wang L, Luo JY, Lau
CW, Liu P, Gao Z, Tipoe GL, Lee HK, et al: Inhibition of miR-200c
restores endothelial function in diabetic mice through suppression
of COX-2. Diabetes. 65:1196–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E,
Yurdusev E and Şahin Ö: MiR-200c: A versatile watchdog in cancer
progression, EMT, and drug resistance. J Mol Med (Berl).
94:629–644. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dimri M, Kang M and Dimri GP: A
miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity
of BMI1 in cancer cells. Oncotarget. 7:36220–36234. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tejero R, Navarro A, Campayo M, Viñolas N,
Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L,
Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brücher BL and Jamall IS: Cell-cell
communication in the tumor microenvironment, carcinogenesis, and
anticancer treatment. Cell Physiol Biochem. 34:213–243. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Li G, Yao ZQ, Moorman JP and Ning
S: MicroRNA regulation of viral immunity, latency, and
carcinogenesis of selected tumor viruses and HIV. Rev Med Virol.
25:320–341. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bizzarri M and Cucina A: Tumor and the
microenvironment: A chance to reframe the paradigm of
carcinogenesis? Biomed Res Int. 2014:9340382014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu S, Tetzlaff MT, Wang T, Yang R, Xie L,
Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, et al: miR-200c/Bmi1
axis and epithelial-mesenchymal transition contribute to acquired
resistance to BRAF inhibitor treatment. Pigment Cell Melanoma Res.
28:431–441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tamagawa S, Beder LB, Hotomi M, Gunduz M,
Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the
regulation of epithelial-mesenchymal transition and migration in
head and neck squamous cell carcinoma. Int J Mol Med. 33:879–886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rajabi H, Alam M, Takahashi H, Kharbanda
A, Guha M, Ahmad R and Kufe D: MUC1-C oncoprotein activates the
ZEB1/miR-200c regulatory loop and epithelial-mesenchymal
transition. Oncogene. 33:1680–1689. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knezevic J, Pfefferle AD, Petrovic I,
Greene SB, Perou CM and Rosen JM: Expression of miR-200c in
claudin-low breast cancer alters stem cell functionality, enhances
chemosensitivity and reduces metastatic potential. Oncogene.
34:5997–6006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gravgaard KH, Lyng MB, Laenkholm AV,
Søkilde R, Nielsen BS, Litman T and Ditzel HJ: The miRNA-200 family
and miRNA-9 exhibit differential expression in primary versus
corresponding metastatic tissue in breast cancer. Breast Cancer Res
Treat. 134:207–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Korpal M, Ell BJ, Buffa FM, Ibrahim T,
Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua
Y, et al: Direct targeting of Sec23a by miR-200s influences cancer
cell secretome and promotes metastatic colonization. Nat Med.
17:1101–1108. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vilming Elgaaen B, Olstad OK, Haug KB,
Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global
miRNA expression analysis of serous and clear cell ovarian
carcinomas identifies differentially expressed miRNAs including
miR-200c-3p as a prognostic marker. BMC Cancer. 14:802014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Toiyama Y, Hur K, Tanaka K, Inoue Y,
Kusunoki M, Boland CR and Goel A: Serum miR-200c is a novel
prognostic and metastasis-predictive biomarker in patients with
colorectal cancer. Ann Surg. 259:735–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang HP, Sun FB and Li SJ: Serum miR-200c
expression level as a prognostic biomarker for gastric cancer.
Genet Mol Res. 14:15913–15920. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Valladares-Ayerbes M, Reboredo M,
Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M,
Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, et al:
Circulating miR-200c as a diagnostic and prognostic biomarker for
gastric cancer. J Transl Med. 10:1862012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Antolin S, Calvo L, Blanco-Calvo M,
Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I,
Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating
miR-200c and miR-141 and outcomes in patients with breast cancer.
BMC Cancer. 15:2972015. View Article : Google Scholar : PubMed/NCBI
|
